As Chief Scientist/Chief Scientific Officer, Weijie Poh, PhD is responsible for the R&D pipeline, diagnostic kit development, and regulatory operations across DLL’s portfolio.
Dr. Poh was previously the Head of Global Medical and Clinical Operations at a digital healthtech company with the number 1 migraine tracking smartphone app in the world. In that role, he was responsible for initiating the first large-scale real-world migraine studies done fully virtually on a digital platform with MNCs such as AbbVie and Nestlé Health Sciences. Prior to that, Dr. Poh was Entrepreneur-in-Residence at Duke-NUS Medical School and was responsible for business development for an infectious disease technology platform. Before that, Dr. Poh cofounded and was CEO of a universal cervical cancer vaccine spinoff from the Johns Hopkins University, during which the company secured federal and private investment for a Phase 1 clinical study in the US.
Dr. Poh has an Ph.D. in Pathobiology from the Johns Hopkins University and completed his postdoctoral training at Harvard Medical School. To date, he has co-authored 12 peer reviewed publications in the fields of sequencing, medical diagnostics, real-world evidence, and cancer biology.